BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35659529)

  • 1. AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation.
    Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106132. PubMed ID: 35659529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
    Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
    Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
    Phanhthilath N; Hakim S; Su C; Liu A; Subramonian D; Lesperance J; Zage PE
    Invest New Drugs; 2020 Dec; 38(6):1677-1686. PubMed ID: 32436058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
    Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
    Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
    Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
    Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.
    Aytatli A; Barlak N; Sanli F; Caglar HO; Gundogdu B; Tatar A; Ittmann M; Karatas OF
    Cell Oncol (Dordr); 2022 Feb; 45(1):41-56. PubMed ID: 34837170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfated polysaccharide of
    Shan L; Liu W; Zhan Y
    Aging (Albany NY); 2019 Sep; 11(18):7780-7795. PubMed ID: 31545294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.
    García-Quiroz J; García-Becerra R; Barrera D; Santos N; Avila E; Ordaz-Rosado D; Rivas-Suárez M; Halhali A; Rodríguez P; Gamboa-Domínguez A; Medina-Franco H; Camacho J; Larrea F; Díaz L
    PLoS One; 2012; 7(9):e45063. PubMed ID: 22984610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
    Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors.
    Kim YJ; Jang SK; Kim G; Hong SE; Park CS; Seong MK; Kim HA; Kim KS; Kim CH; Park KS; Hong J; Jin HO; Park IC
    Anticancer Res; 2023 May; 43(5):1973-1980. PubMed ID: 37097659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
    Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
    Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
    Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.